Baidu
map

感染

订阅

MedSci主页 / 所有栏目 / 感染

JAMA：美罗培南- Vaborbactam治疗复杂性尿路感染疗效及安全性良好

2018-02-28 zhangfan MedSci原创

复杂性尿路感染美罗培南Vaborbactam
关注

研究认为对于复杂性尿路感染患者，美罗培南- Vaborbactam可显著改善患者症状，提高致病微生物清除率并且安全性良好

碳青霉烯/β-内酰胺酶抑制剂联用治疗严重耐药性革兰氏阴性感染的方法。近日研究人员考察了美罗培南- Vaborbactam对治疗复杂性尿路感染(UTI)，包括急性肾盂肾炎的疗效和安全性。

本次III期临床研究招募18岁以上复杂UTI患者，根据感染类型和区域分层，患者随机接受3小时，2g/2g的美罗培南- Vaborbactam治疗（n=274）或30min，4g/0.5g哌拉西林-他佐巴坦（n？=？276），每8小时给药一次。接受15次或以上治疗后，症状改善患者可接受口服左氧氟沙星治疗，直至完成10天的治疗期。研究的主要终点为临床治愈、改善以及致病微生物根除的复合终点。

545人参与研究，平均年龄52.8岁，女性占66.2%，93.2%的患者完成研究。研究发现，美罗培南- Vaborbactam治疗组98.4%的患者达到主要终点，哌拉西林-他佐巴坦组94.0%的患者达到主要终点。治疗意向人群中，致病微生物根除率，美罗培南- Vaborbactam vs哌拉西林-他佐巴坦为66.7% vs 57.7%，差异为9%；致病微生物评估人群中，致病微生物根除率，美罗培南- Vaborbactam vs哌拉西林-他佐巴坦为66.3% vs 60.4%，差异为5.9%。不良事件率，美罗培南- Vaborbactam vs哌拉西林-他佐巴坦为39.0% vs 35.5%。

研究认为对于复杂性尿路感染患者，美罗培南- Vaborbactam可显著改善患者症状，提高致病微生物清除率并且安全性良好。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849585, encodeId=6cc4184958595, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Sep 15 10:16:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651401, encodeId=6d921651401ee, content=<a href='/topic/show?id=4b64e998681' target=_blank style='color:#2F92EE;'>#美罗培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79986, encryptionId=4b64e998681, topicName=美罗培南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061b24191563, createdName=fanweitanzhen, createdTime=Tue May 08 16:16:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587237, encodeId=7e22158e237ae, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598001, encodeId=98f315980016b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291745, encodeId=8cbb291e45b3, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:52 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291697, encodeId=b54e29169efa, content=医学是不断创新中成长起来的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Wed Feb 28 12:37:19 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-09-15 windight

    #CTA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1849585, encodeId=6cc4184958595, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Sep 15 10:16:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651401, encodeId=6d921651401ee, content=<a href='/topic/show?id=4b64e998681' target=_blank style='color:#2F92EE;'>#美罗培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79986, encryptionId=4b64e998681, topicName=美罗培南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061b24191563, createdName=fanweitanzhen, createdTime=Tue May 08 16:16:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587237, encodeId=7e22158e237ae, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598001, encodeId=98f315980016b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291745, encodeId=8cbb291e45b3, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:52 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291697, encodeId=b54e29169efa, content=医学是不断创新中成长起来的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Wed Feb 28 12:37:19 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-05-08 fanweitanzhen

    #美罗培南#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1849585, encodeId=6cc4184958595, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Sep 15 10:16:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651401, encodeId=6d921651401ee, content=<a href='/topic/show?id=4b64e998681' target=_blank style='color:#2F92EE;'>#美罗培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79986, encryptionId=4b64e998681, topicName=美罗培南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061b24191563, createdName=fanweitanzhen, createdTime=Tue May 08 16:16:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587237, encodeId=7e22158e237ae, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598001, encodeId=98f315980016b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291745, encodeId=8cbb291e45b3, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:52 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291697, encodeId=b54e29169efa, content=医学是不断创新中成长起来的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Wed Feb 28 12:37:19 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-03-02 minlingfeng

    #复杂性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1849585, encodeId=6cc4184958595, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Sep 15 10:16:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651401, encodeId=6d921651401ee, content=<a href='/topic/show?id=4b64e998681' target=_blank style='color:#2F92EE;'>#美罗培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79986, encryptionId=4b64e998681, topicName=美罗培南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061b24191563, createdName=fanweitanzhen, createdTime=Tue May 08 16:16:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587237, encodeId=7e22158e237ae, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598001, encodeId=98f315980016b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291745, encodeId=8cbb291e45b3, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:52 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291697, encodeId=b54e29169efa, content=医学是不断创新中成长起来的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Wed Feb 28 12:37:19 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-03-02 闆锋旦

    #ABO#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1849585, encodeId=6cc4184958595, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Sep 15 10:16:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651401, encodeId=6d921651401ee, content=<a href='/topic/show?id=4b64e998681' target=_blank style='color:#2F92EE;'>#美罗培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79986, encryptionId=4b64e998681, topicName=美罗培南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061b24191563, createdName=fanweitanzhen, createdTime=Tue May 08 16:16:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587237, encodeId=7e22158e237ae, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598001, encodeId=98f315980016b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291745, encodeId=8cbb291e45b3, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:52 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291697, encodeId=b54e29169efa, content=医学是不断创新中成长起来的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Wed Feb 28 12:37:19 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-02-28 梦想起航ing

    学习了.有用.谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1849585, encodeId=6cc4184958595, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Sep 15 10:16:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651401, encodeId=6d921651401ee, content=<a href='/topic/show?id=4b64e998681' target=_blank style='color:#2F92EE;'>#美罗培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79986, encryptionId=4b64e998681, topicName=美罗培南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=061b24191563, createdName=fanweitanzhen, createdTime=Tue May 08 16:16:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587237, encodeId=7e22158e237ae, content=<a href='/topic/show?id=9b4a42e01ed' target=_blank style='color:#2F92EE;'>#复杂性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42701, encryptionId=9b4a42e01ed, topicName=复杂性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19f17453483, createdName=minlingfeng, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598001, encodeId=98f315980016b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Mar 02 01:16:00 CST 2018, time=2018-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291745, encodeId=8cbb291e45b3, content=学习了.有用.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Wed Feb 28 17:09:52 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291697, encodeId=b54e29169efa, content=医学是不断创新中成长起来的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Wed Feb 28 12:37:19 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-02-28 祝您健康

    医学是不断创新中成长起来的!

    0

Baidu
map
Baidu
map
Baidu
map